Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/307254
COMPARTIR / EXPORTAR:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE

Invitar a revisión por pares abierta
Título

Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology

AutorCalleja, José Luis; Rivera-Esteban, Jesús; Aller, Rocío; Hernández-Conde, Marta; Abad, Javier; Pericás Pulico, Juan Manuel; Benito, Hugo G.; Serra, Miguel Ángel; Escudero, Amparo; Ampuero, Javier CSIC ORCID; Lucena, Ana; Sánchez-Torrijos, Yolanda CSIC; Arias-Loste, María Teresa; Iruzubieta, Paula; Romero-Gómez, Manuel CSIC ORCID CVN; Augustin, Salvador; Crespo, Javier CSIC
Palabras claveHepatic fibrosis
Liver biopsy
Non-alcoholic steatohepatitis
Transient elastography
Fecha de publicaciónago-2022
EditorJohn Wiley & Sons
CitaciónLiver International 42(8): 1783-1792 (2022)
Resumen[Background & Aims] Non-alcoholic fatty liver disease (NAFLD) has become a major public health problem, but the prevalence of fibrosis associated with non-alcoholic steatohepatitis (NASH) is largely unknown in the general population. This study aimed to provide an updated estimation of the prevalence of NASH fibrosis in Spain.
[Methods] This was an observational, retrospective, cross-sectional, population-based study with merged data from two Spanish datasets: a large (N = 12 246) population-based cohort (ETHON), including transient elastography (TE) data, and a contemporary multi-centric biopsy-proven NASH cohort with paired TE data from tertiary centres (N = 501). Prevalence for each NASH fibrosis stage was estimated by crossing TE data from ETHON dataset with histology data from the biopsy-proven cohort.
[Results] From the patients with valid TE in ETHON dataset (N = 11 440), 5.61% (95% confidence interval [95% CI]: 2.53-11.97) had a liver stiffness measurement (LSM) ≥ 8 kPa. The proportion attributable to NAFLD (using clinical variables and Controlled Attenuation Parameter) was 57.3% and thus, the estimated prevalence of population with LSM ≥ 8 kPa because of NAFLD was 3.21% (95% CI 1.13–8.75). In the biopsy-proven NASH cohort, 389 patients had LSM ≥ 8 kPa. Among these, 37% did not have significant fibrosis (F2-4). The estimated prevalence of NASH F2-3 and cirrhosis in Spain's adult population were 1.33% (95% CI 0.29–5.98) and 0.70% (95% CI 0.10–4.95) respectively.
[Conclusions] These estimations provide an accurate picture of the current prevalence of NASH-related fibrosis in Spain and can serve as reference point for dimensioning the therapeutic efforts that will be required as NASH therapies become available.
Versión del editorhttps://doi.org/10.1111/liv.15323
URIhttp://hdl.handle.net/10261/307254
DOI10.1111/liv.15323
ISSN1478-3223
E-ISSN1478-3231
Aparece en las colecciones: (IBIS) Artículos




Ficheros en este ítem:
Fichero Descripción Tamaño Formato
Prevalence_estimation_Calleja.pdf591,11 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo

CORE Recommender

PubMed Central
Citations

4
checked on 18-mar-2024

SCOPUSTM   
Citations

8
checked on 21-mar-2024

WEB OF SCIENCETM
Citations

7
checked on 25-feb-2024

Page view(s)

31
checked on 28-mar-2024

Download(s)

19
checked on 28-mar-2024

Google ScholarTM

Check

Altmetric

Altmetric


Artículos relacionados:


Este item está licenciado bajo una Licencia Creative Commons Creative Commons